Kymera Therapeutics annual revenue
2019
2020
2021
2022
2023
2024
2025
Kymera Therapeutics Revenue Growth & History (KYMR)
Kymera Therapeutics reported $39.2M in revenue for fiscal 2025, a decrease of 16.70% from the previous fiscal year.
View full Kymera Therapeutics company overviewKymera Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $39.2M | −$7.9M | −16.70% |
| 2024 | 2024-12-31 | $47.1M | −$31.5M | −40.11% |
| 2023 | 2023-12-31 | $78.6M | $31.8M | +67.84% |
| 2022 | 2022-12-31 | $46.8M | −$26.0M | −35.71% |
| 2021 | 2021-12-31 | $72.8M | $38.8M | +114.00% |
| 2020 | 2020-12-31 | $34.0M | $31.1M | +1059.99% |
| 2019 | 2019-12-31 | $2.9M | — | — |
Kymera Therapeutics quarterly revenue
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $65.0M | $53.5M | +466.40% |
| Q1 2026 | 2026-03-31 | $34.4M | $12.3M | +55.50% |
| Q4 2025 | 2025-12-31 | $2.9M | −$4.5M | −61.17% |
| Q3 2025 | 2025-09-30 | $2.8M | −$977,000 | −26.12% |
| Q2 2025 | 2025-06-30 | $11.5M | −$14.2M | −55.26% |
| Q1 2025 | 2025-03-31 | $22.1M | $11.8M | +114.83% |
| Q4 2024 | 2024-12-31 | $7.4M | −$40.5M | −84.56% |
| Q3 2024 | 2024-09-30 | $3.7M | −$987,000 | −20.88% |
| Q2 2024 | 2024-06-30 | $25.6M | $9.1M | +55.33% |
| Q1 2024 | 2024-03-31 | $10.3M | $821,000 | +8.67% |
| Q4 2023 | 2023-12-31 | $47.9M | $31.7M | +196.70% |
| Q3 2023 | 2023-09-30 | $4.7M | −$4.8M | −50.50% |
| Q2 2023 | 2023-06-30 | $16.5M | $5.0M | +43.42% |
| Q1 2023 | 2023-03-31 | $9.5M | −$156,000 | −1.62% |
| Q4 2022 | 2022-12-31 | $16.1M | $864,000 | +5.66% |
| Q3 2022 | 2022-09-30 | $9.6M | −$10.8M | −53.03% |
| Q2 2022 | 2022-06-30 | $11.5M | −$7.0M | −37.83% |
| Q1 2022 | 2022-03-31 | $9.6M | −$9.1M | −48.55% |
| Q4 2021 | 2021-12-31 | $15.3M | $2.5M | +19.48% |
| Q3 2021 | 2021-09-30 | $20.3M | $5.8M | +39.93% |
| Q2 2021 | 2021-06-30 | $18.5M | $15.2M | +463.23% |
| Q1 2021 | 2021-03-31 | $18.7M | $15.3M | +445.57% |
| Q4 2020 | 2020-12-31 | $12.8M | — | — |
| Q3 2020 | 2020-09-30 | $14.5M | $13.6M | +1429.79% |
| Q2 2020 | 2020-06-30 | $3.3M | — | — |
| Q1 2020 | 2020-03-31 | $3.4M | — | — |
| Q3 2019 | 2019-09-30 | $950,000 | — | — |
Kymera Therapeutics revenue growth trends
Over the last five reported fiscal years, revenue grew from $34.0M to $39.2M, a compound annual growth rate of 2.87%. Kymera Therapeutics's latest reported quarter, Q2 2026, generated $65.0M in revenue, an increase of 466.40% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Kymera Therapeutics source filings ↗